The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Expected Market Size Of The Duchenne Muscular Dystrophy Market From 2026 To 2030?
The duchenne muscular dystrophy market has seen significant expansion in recent years. It is anticipated to increase from $1.25 billion in 2025 to $1.35 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.9%. The market’s historical growth can be attributed to a higher prevalence of duchenne muscular dystrophy, breakthroughs in molecular biology techniques, enhanced awareness regarding rare genetic disorders, the development of tools for early diagnosis, and more extensive research collaborations between academic and pharmaceutical institutions.
The duchenne muscular dystrophy market is projected for significant expansion in the coming years, anticipated to reach $1.87 billion by 2030, demonstrating an 8.5% compound annual growth rate. This expansion during the forecast period is fueled by increasing adoption of gene therapies, broader application of precision medicine, enhanced investment in developing drugs for rare diseases, incentives from regulators for orphan drugs, and the incorporation of digital health solutions into patient care. Key trends expected over the forecast horizon encompass progress in gene editing, individualized treatment plans, increased funding for rare disease research, healthcare models centered on patients, and the ongoing development of orphan drugs.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10368&type=smp
What Key Drivers Are Influencing The Growth Of The Duchenne Muscular Dystrophy Market?
The future expansion of the Duchenne muscular dystrophy market is anticipated to be driven by the rising incidence of chronic ailments. Specifically, a chronic disease refers to a health condition characterized by symptoms that persist for a minimum of one year. The Duchenne muscular dystrophy market plays a role in the context of chronic diseases by catering to the particular treatment requirements of those affected by this genetic disorder, thereby underscoring the wider importance of tailored medical approaches for handling and potentially lessening the effects of long-term health issues. For example, data from January 2023, provided by the National Library of Medicine, a US-based government agency, indicates that the population in the US aged 50 and older experiencing at least 1 chronic condition is projected to rise to 142.66 million by the year 2050. Consequently, the growing occurrence of chronic diseases is a key factor propelling the development of the Duchenne muscular dystrophy market.
Which Segments Are Included In The Analysis Of The Duchenne Muscular Dystrophy Market?
The duchenne muscular dystrophy market covered in this report is segmented –
1) By Therapy: Mutation Suppression, Exon Skipping Approach
2) By Therapeutic Class: Molecular Based Therapies, Steroid Therapy
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Mutation Suppression: Antisense Oligonucleotides (ASOs), Small Molecules, Gene Therapy
2) By Exon Skipping Approach: Exon-Skipping Therapies, Combination Therapies, Clinical Trials And Investigational Drugs
Which Trends Are Impacting The Growth Of The Duchenne Muscular Dystrophy Market?
Major companies operating in the Duchenne muscular dystrophy market are advancing technology, particularly in clinical trial design, to improve the efficiency and effectiveness of drug development processes, enhance patient outcomes, and accelerate the approval of new therapies. Clinical trial design is the method of organizing and planning a clinical trial to assess a novel treatment’s safety and efficacy, including setting goals, choosing participants, and outlining methods and analyses. For instance, in March 2024, Critical Path Institute (C-Path), a US-based non-profit organization, introduced the DMD Clinical Trial Simulator (CTS). This innovative tool, developed by C-Path’s Duchenne Regulatory Science Consortium, aims to optimize the design of efficacy studies for DMD therapies. Key features of the CTS include advanced modeling of functional test performance, the capability to simulate various scenarios, increased efficiency in trial design, and public accessibility via the C-Path website and the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP). As such, it serves as a valuable resource for researchers and pharmaceutical companies engaged in DMD research.
Which Key Industry Participants Are Active In The Duchenne Muscular Dystrophy Market?
Major companies operating in the duchenne muscular dystrophy market are Pfizer Inc., GlaxoSmithKline plc, BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Asklepios BioPharmaceutical Inc., Catabasis Pharmaceuticals Inc., Wave Life Sciences Ltd., Bristol Myers Squibb Company, BridgeBio Pharma Inc., Rocket Pharmaceuticals Inc., Italfarmaco SpA, Solid Biosciences Inc., Avidity Biosciences Inc., Fulcrum Therapeutics Inc., Akashi Therapeutics Inc., Capricor Therapeutics Inc., Santhera Pharmaceuticals Holding, Armagen Technologies Inc., Dyne Therapeutics Inc., Benitec Biopharma Limited, Edgewise Therapeutics Inc., WAVE Life Sciences Ltd.
Read the full duchenne muscular dystrophy market report here:
https://www.thebusinessresearchcompany.com/report/duchenne-muscular-dystrophy-global-market-report
Which Region Is Expected To Register The Fastest Growth In The Duchenne Muscular Dystrophy Market?
North America was the largest region in the Duchenne muscular dystrophy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global duchenne muscular dystrophy market during the forecast period. The regions covered in the duchenne muscular dystrophy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Duchenne Muscular Dystrophy Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=10368&type=smp
Browse Through More Reports Similar to the Global Duchenne Muscular Dystrophy Market 2026, By The Business Research Company
Duchenne Muscular Dystrophy Market Report 2026
https://www.thebusinessresearchcompany.com/report/duchenne-muscular-dystrophy-global-market-report
Duchenne Muscular Dystrophy Dmd Therapeutics Market Report 2026
Muscle Wasting Disorders Market Report 2026
https://www.thebusinessresearchcompany.com/report/muscle-wasting-disorders-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model